Eyevansys initiates trial for PST-611 in dry AMD assessing safety and tolerability
Eyevansys is conducting a clinical trial to evaluate the safety and tolerability of PST-611 in patients with dry AMD.
Therapeutic Area
Therapeutic area intelligence for Dry Age-related Macular Degeneration with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.